Clinical

Investigators using real-world data found that patients receiving treatment from slow mist inhalers (SMIs) had fewer exacerbations and hospitals readmissions compared with patients using dry powder inhalers (DPIs).

Among the viewpoints offered by the authors to overcome barriers in solving unmet needs in pulmonary arterial hypertension (PAH) are preclinical pipelines for drug repurposing, working around challenges in early-stage trial design, and refining target selection and demonstration of engagement.

Emerging research into natural killer cells has shown promise, but the findings are complicated by the heterogeneity of multiple myeloma (MM).

Data on patients with migraine who stopped erenumab treatment show that over half of patients had an early disease worsening while the remaining patients maintained their responder status during weeks 1 through 4 post treatment.

A recent study evaluated the content validity of patient-reported outcome instruments used in low-risk myelodysplastic syndrome (MDS).

The FDA decision on dapaglifozin for CKD is expected in the second quarter of 2021.

Complete response to first-line therapy, as determined by the International Working Group 2006 response criteria, can be used as a surrogate end point for overall survival in higher-risk patients with myelodysplastic syndromes (MDS), according to a study published in Cancer Medicine.

A new study from Sweden cautions against routine discontinuation of renin-angiotensin system (RAS) inhibitors in patients with chronic kidney disease (CKD).

Chimeric antigen receptor (CAR) T-cell exhaustion likely stems from chemotherapy prior to transplant, noted Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.

Coronavirus disease 2019 (COVID-19) dominated 2020. This is a look back at how the pandemic evolved and progressed through the year, which closed with the arrival of vaccines, but also continued challenges.

Questions remain about the optimal approach to transfusion management in myelodysplastic syndromes (MDS), particularly in the outpatient setting, leading a pair of researchers to review current evidence.

Matthew J. Zirwas, MD, a dermatologist in Ohio, discusses how dermatologists may stratify patients with atopic dermatitis (AD) with the launch of new biologic treatments in 2021.

The top 5 most-read Parkinson disease stories of 2020 on AJMC.com included the latest insights on treatments such as spinal cord stimulation and the role of dietary management, as well as implications of the coronavirus disease 2019 pandemic.

Premature coronary artery disease (CAD) is an aggressive disease with a high rate of ischemic recurrences and premature death, researchers said.

This approach allows clinicians to keep using existing prediction models and incorporate chronic kidney disease (CKD) data seamlessly to calibrate patients' risks, said Kunihiro Matsushita, MD, an associate professor in the Department of Epidemiology and Division of Cardiology at Johns Hopkins University.

New research shows metabolic biomarkers could be meaningful tools for predicting treatment outcomes in patients, based on a comparison of biomarkers, clinical characteristics, and therapeutic efficacy.

A recent study sought to estimate the incidence of clinical events such as bleeding, myocardial infarction, and all-cause mortality in patients with acute myocardial infarction and chronic coronary syndrome who received dual antiplatelet therapy (DAPT) after coronary stenting.

Our 5 most-read oncology stories and most-watched videos this year highlighted cancer care policy, diversity, and the growing practice of remote cancer care.

Two story lines predominated renal news in 2020: coronavirus disease 2019's effect on the kidneys and the overwhelming benefits of sodium-glucose cotransporter 2 inhibitors for those with chronic kidney disease and type 2 diabetes.

The review of 32 studies revealed that biologic treatment tended to favor patients with allergic bronchopulmonary aspergillosis (ABPA) and asthma rather than those with cystic fibrosis (CF).

This year’s top 5 most-read stories in lung cancer were overrun by non–small cell lung cancer drug trial results and FDA action.

A study from Denmark found that low health literacy was not a risk factor for mortality in patients with chronic obstructive pulmonary disease (COPD) compared with the general population and patients with other chronic conditions.

Researchers sought to gain a better understanding of the relationship between genetic mutations in metastatic colon cancer (mCRC), advanced disease, and locations of primary tumors.

The FDA has approved Margenza (margetuximab-cmkb) plus chemotherapy as a treatment option for adults with HER2-postive advanced breast cancer.